ZNF816 and psoriasis: SNPs in TLR2, TNF, SLC12A8, ZNF816A and TNFAIP3 genes were associated with 3-month response (measured as PASI90 and absolute PASI < 1) to Secukinumab and Ixekinumab in 19 psoriasis patients [22].